MEDIHONEY Used to Prevent Amputation of Patient's Leg

Clinicians at major NY hospital tout MEDIHONEY(TM) at press conference

PRINCETON, N.J., Jan. 13 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC
Bulletin Board: DSCI), a provider of advanced wound care products, announced
today that MEDIHONEY was the focus of a major press conference last week at
North Shore Long Island Jewish Hospital in Manhasset, NY. At the press
conference, clinicians detailed the case of a patient who appeared to be
heading towards a lower extremity amputation (LEA) due to a non-healing wound
associated with an extremely rare fungal infection.

Video clips of the press conference were subsequently aired on several new
broadcasts throughout the NY region. To view these clips, please go to the
following links:

http://www.newsday.com/news/health/ny-lihone0109,0,7667575.story

http://abclocal.go.com/wabc/story?section=news/health&id=6593764

According to Mary Brennan, RN, CWOCN, Clinical Nurse Specialist for Wounds at
North Shore, "MEDIHONEY helped to turn this wound around for him and allowed
us back on track for healing. We had used other therapies, but this was the
product that made the difference in a very short time."

There are over 50,000 LEAs each year in the United States alone. The 3-year
mortality rate post-LEA is estimated to be around 50%.

About Derma Sciences
Derma Sciences is a global manufacturer and marketer of advanced wound-care
products. Its key product, MEDIHONEY(R), is sold throughout the world by Derma
Sciences and Comvita New Zealand -- the licensor of the patented honey- based
technology -- and is the leading brand of honey-based dressings for the
management of wounds and burns. The product has been shown to be effective in
a variety of wounds and burns, and was recently the focus of a large-scale
randomized controlled trial on leg ulcers. Derma has two products in
development: the BIOGUARD(TM) line of barrier gauze dressings, and DSC127, the
company's novel angiotensin analog for accelerated wound healing and scar
reduction. The barrier technology was licensed from Quick-Med in Q1 of 2007
and is pending its initial FDA marketing clearance. DSC127 was licensed from
the University of Southern California in Q4 of 2007. For more information
about Derma Sciences, Inc., visit its home page on the Internet at
http://www.dermasciences.com.

Contact: Derma Sciences, Inc. Allen & Caron Inc
Edward J. Quilty Rudy Barrio (US Investors)
Chairman and CEO r.barrio@allencaron.com
equilty@dermasciences.com
(609) 514-4744 Brian Kennedy (media)
brian@allencaron.com
(212) 691-8087

SOURCE Derma Sciences, Inc.

Edward J. Quilty, Chairman and CEO of Derma Sciences, Inc., +1-609-514-4744,
equilty@dermasciences.com; or Rudy Barrio (US Investors)
r.barrio@allencaron.com, or Brian Kennedy (media), +1-212-691-8087,
brian@allencaron.com, both of Allen & Caron Inc